MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

Search

Insmed

Avatud

SektorTervishoid

153.71 5.22

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

146.13

Max

153.86

Põhinäitajad

By Trading Economics

Sissetulek

-65M

-322M

Müük

15M

107M

Aktsiakasum

-1.7

Kasumimarginaal

-299.48

Töötajad

1,271

EBITDA

-47M

-295M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+10.44% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

30. okt 2025

Turustatistika

By TradingEconomics

Turukapital

9.2B

30B

Eelmine avamishind

148.49

Eelmine sulgemishind

153.71

Uudiste sentiment

By Acuity

40%

60%

115 / 371 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

Insmed Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

10. juuni 2025, 12:53 UTC

Suurimad hinnamuutused turgudel

Insmed Shares Rise on Positive Results From Study of Treatment for High Blood Pressure in Lungs

Võrdlus sarnastega

Hinnamuutus

Insmed Prognoos

Hinnasiht

By TipRanks

10.44% tõus

12 kuu keskmine prognoos

Keskmine 162.65 USD  10.44%

Kõrge 240 USD

Madal 138 USD

Põhineb 18 Wall Streeti analüütiku instrumendi Insmed 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

18 ratings

17

Osta

1

Hoia

0

Müü

Tehniline skoor

By Trading Central

N/A / 69.2Toetus ja vastupanu

Lühikene perspektiiv

Very Strong Bearish Evidence

Keskpikk perspektiiv

Very Strong Bearish Evidence

Pikk perspektiiv

Weak Bearish Evidence

Sentiment

By Acuity

115 / 371 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Insmed

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary hypertension associated with interstitial lung disease and pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
help-icon Live chat